Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with Anti-IgE antibody (Omalizumab)

Pediatric Pulmonology

Volumn 43, Issue 12, 2008, Pages 1249-1251

  Kanu, Adaobi ^a   Patel, Kalpana ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Allergic bronchopulmonary aspergillosis; Cystic fibrosis; Monoclonal anti IgE antibody

Indexed keywords

ITRACONAZOLE; OMALIZUMAB; PREDNISONE;

ADOLESCENT; ARTICLE; BRONCHOPULMONARY ASPERGILLOMA; CASE REPORT; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSURIA; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LUNG FUNCTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOOD DISORDER; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; CYSTIC FIBROSIS; FEMALE; HUMANS; PULMONARY ASPERGILLOSIS; TREATMENT OUTCOME;

EID: 56849094458     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20907     Document Type: Article

References (21)

1. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, Skov M, Maish W, Mastella G, participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis - state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003;37:S225-S264.
2. Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Chest 1999;116:639-646.
3. Mastella G, Rainisio M, Harms HK, Hodson ME, Koch C, Navarro J, Strandvik B, McKenzie SG. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A. European epidemiological study. Epidemiologic Registry Cystic Fibrosis. Eur Respir J 2000;16:464-471.
4. de Almeida MB, Bussamra MHF, Rodrigues JC. Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr Respir Rev 2006;7:67-72.
5. Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy 2005;60:1004-1013.
6. Gibson PG. Allergic bronchopulmonary aspergillosis. Semin Respir Crit Care Med 2006;27:185-191.
7. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, Bamberger DM, Neinmann AJ, Tauzon CU, Judson MA, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Eng J Med 2000;342:756-762.
8. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007;62:276-277.
9. Hendeles L, Sorkness CA. Anti-Immunoglobulin E therapy with omalizumab for asthma. Ann Pharmacother 2007;41:1397-1410.
10. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-261.
11. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-190.
12. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125:1378-1386.
13. Knutsen AP, Hutchinson PS, Albers GM, Consolino J, Smick J, Kurup VP. Increased sensitivity to IL 4 in cystic fibrosis patients with allergic bronchopulmonary aspergillosis. Allergy 2004;59:81-87.
14. Knutsen AP, Hutcheson PS, Slavin RG, Kurup VP. IgE antibody to aspergillus fumigatus recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis. Allergy 2004;59:198-203.
15. Knutsen AP, Mueller KR, Hutchenson PS, Slavin RG. T and B cell dysregulation of IgE synthesis in cystic fibrosis patients with allergic bronchopulmonary aspergillosis. Clin Immunol Immunopathol 1990;55:129-138.
16. Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med 2006;100:1907-1917.
17. Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody. Medscape Gen Med 2005;7:27.
18. Costa M, Potvin S, Berthiaume Y, Gauthier L, Jeanneret A, Lavore A, Levesque R, Chiasson J, Rabasa-Lhoet R. Diabetes: a major comorbidity of cystic fibrosis. Diabetes Metab 2005;31:221-232.
19. Buntain HM, Schluter PJ, Bell SC, Greer RM, Wong JC, Batch J, Lewindon P, Wainwright CE. Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. Thorax 2006;61:146-154.
20. Byard PJ. Early childhood growth in patients with cystic fibrosis. Ann Hum Biol 1990;17:483-499.
21. Byard PJ. The adolescent growth spurt in children with cystic fibrosis. Ann Hum Biol 1994;21:229-240.